Evaluating the accuracy of monitoring seizure cycles with seizure diaries

Abstract

Objective

Epileptic seizures occurring in cyclical patterns is increasingly recognized as a significant opportunity to advance epilepsy management. Current methods for detecting seizure cycles rely on intrusive techniques or specialized biomarkers, thereby limiting their accessibility. This study evaluates a non-invasive seizure cycle detection method using seizure diaries and compares its accuracy with cycles identified from intracranial electroencephalography (iEEG) seizures and interictal epileptiform discharges (IEDs).

Methods

Using data from a previously published first in-human iEEG device trial (n = 10), we analyzed seizure cycles identified through ...

Seguir leyendo →
0

The epilepsy–autism phenotype associated with developmental and epileptic encephalopathies: New mechanism‐based therapeutic options

Abstract

Epilepsy and autism often co-occur in genetic developmental and epileptic encephalopathies (DEEs), but their underlying neurobiological processes remain poorly understood, complicating treatment. Advances in molecular genetics and understanding the neurodevelopmental pathogenesis of the epilepsy–autism phenotype may lead to mechanism-based treatments for children with DEEs and autism. Several genes, including the newly reported PPFIA3, MYCBP2, DHX9, TMEM63B, and RELN, are linked to various neurodevelopmental and epileptic disorders, intellectual disabilities, and autistic features. These findings underscore the clinical heterogeneity of genetic DEEs ...

Seguir leyendo →
0

Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy

Abstract

Objective

Cannabidiol (CBD) (Epidyolex) is a new antiseizure medication (ASM) for rare and severe epileptic syndromes. We aimed to investigate the pharmacokinetic variability of CBD to elucidate relationships between doses, serum concentrations, metabolites, and biochemical markers of toxicity by using therapeutic drug monitoring (TDM) data.

Methods

Data on serum concentrations of all ASMs, CBD, and the active metabolite 7-hydroxy-cannabidiol (7-OH-CBD) were collected (January 2022 to June 2023) at the Section for Clinical Pharmacology, National Centre for Epilepsy, Oslo University Hospital.

Results

Data from 52 patients ...

Seguir leyendo →
0

Enlarged perivascular space in the temporal lobe as a prognostic marker in temporal lobe epilepsy with hippocampal sclerosis

Abstract

Objective

This study was undertaken to investigate the regional burden of enlarged perivascular spaces (EPVSs) in patients with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) and explore its prognostic relevance.

Methods

In this retrospective observational study, EPVSs in the temporal lobe (T-EPVS), centrum semiovale (CS-EPVS), basal ganglia (BG-EPVS), midbrain, and hippocampus were visually rated in 68 treatment-naïve patients with TLE-HS. Regional EPVS burden was dichotomized into high and low degrees (cutoff: >10 for BG-EPVS/T-EPVS; >20 for CS-EPVS). Cox proportional hazards models were used ...

Seguir leyendo →
0

Voluntary running wheel activity reduces seizure burden and affords neuroprotection in a mouse model of acquired epilepsy

Abstract

Objective

Physical exercise may improve neurological deficits and neuronal damage after acute brain injuries and decrease established seizures. We investigated whether voluntary running wheel (RW) activity affects epileptogenesis in a mouse model of acquired epilepsy compared to sedentary mice.

Methods

Epilepsy was induced by intra-amygdala kainate causing status epilepticus (SE) in adult male mice. Sham mice were implanted with electrodes and injected with saline, and matched to experimental mice. In the RW-1 protocol, SE mice were trained to run for 5 weeks before SE ...

Seguir leyendo →
0

Perioperative clinical and radiological predictors of late post‐traumatic seizures in surgically treated patients with depressed skull fractures: A prospective observational study

Abstract

Objective

This study aimed to identify perioperative clinical and radiological factors that predict the risk of developing late posttraumatic seizures (PTS) within 24 months of injury among surgically managed traumatic brain injury (TBI) patients with depressed skull fracture (DSF).

Methods

A prospective cohort study was conducted at Mulago Hospital, Uganda, involving mild-to-moderate TBI patients with DSF, followed up perioperatively and at outpatient clinics, and additionally via phone interviews for up to 24 months. The study monitored the incidence and recurrence of late PTS.

Results

The cohort included ...

Seguir leyendo →
0

Focal to bilateral tonic–clonic seizures in newly diagnosed focal epilepsy

Abstract

Presence of focal to bilateral tonic–clonic seizures (FBTCS) in focal epilepsy is associated with increased morbidity and mortality. Risk factors for FBTCS are poorly understood, and little is known regarding FBTCS recurrence after treatment initiation. This study aimed to investigate factors related to FBTCS in newly diagnosed focal epilepsy and their recurrence after starting antiseizure medications (ASMs) in the Human Epilepsy Project (HEP) cohort. HEP was an international, prospective cohort study that enrolled people with newly diagnosed focal epilepsy within ...

Seguir leyendo →
0

Cytomegalic parvalbumin neurons in fetal cases of hemimegalencephaly

Abstract

Objective

Mutations in genes of the mTOR pathway have been identified as a major cause of hemimegalencephaly (HMG), focal cortical dysplasia type II, and tuberous sclerosis, cortical malformations associated with epilepsy. These conditions are characterized at the cellular level by increased size of pyramidal neurons that grow with dysmorphic features and in some cases by the presence of giant balloon cells. Our previous research in tuberous sclerosis has shown that parvalbumin (Pvalb) and calbindin immunoreactive cells in cortical and subcortical tuberal ...

Seguir leyendo →
0

A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat

Abstract

Soticlestat (TAK-935) is a potent and selective inhibitor of cholesterol 24-hydroxylase (CYP46A1), an enzyme primarily expressed in the brain that catabolizes cholesterol to 24S-hydroxycholesterol (24HC). In the ELEKTRA phase II clinical trial, soticlestat reduced seizure frequency in patients with developmental and epileptic encephalopathies, and two phase III studies evaluating the safety and efficacy of soticlestat in Dravet syndrome (SKYLINE) and Lennox–Gastaut syndrome (SKYWAY) have recently been completed. The exact mechanism of action by which soticlestat exerts pharmacological benefits remains undetermined. ...

Seguir leyendo →
0

Cognitive and brain health in juvenile myoclonic epilepsy: Role of social determinants of health

Abstract

Objective

Juvenile myoclonic epilepsy (JME) is a prevalent genetic generalized epilepsy with linked abnormalities in cognition, behavior, and brain structure. Well recognized is the potential for advancing understanding of the epigenetic contributions to the neurobehavioral complications of JME, but to date there has been no examination of the role of socioeconomic disadvantage in regard to the cognitive and brain health of JME, which is the focus of this investigation.

Methods

Seventy-seven patients with JME and 44 unrelated controls underwent neuropsychological assessment, structural neuroimaging, ...

Seguir leyendo →
0
Página 23 de 275 «...10202122232425...»